Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9

Clinical Drug Investigation

Volumn 33, Issue 12, 2013, Pages 877-883

  Guo, Yuan Lin ^a   Liu, Jun ^a   Xu, Rui Xia ^a   Zhu, Cheng Gang ^a   Wu, Na Qiong ^a   Jiang, Li Xin ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 PROTEIN; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; PYRROLES; SERINE ENDOPEPTIDASES;

EID: 84890264853     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0129-2     Document Type: Article

References (21)

1. Lambert G, Sjouke B, Choque B, et al. The PCSK9 decade. J Lipid Res. 2012;53:2515-24.
2. Cariou B, May CL, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258-65.
3. Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J Intern Med. 2009;266:507-19.
4. Maxwell KN, Soccio RE, Duncan EM, et al. Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res. 2003;44:2109-19.
5. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24:1454-9.
6. Khera A. Statin, plasma proprotein convertase subtilisin/kexin type 9 concentrations, and LDL lowering. Clin Chem. 2012;58:6-7.
7. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res. 2008;49:394-8.
8. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51:2714-21.
9. Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res. 2010;51:1486-95.
10. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498-511.
11. Guo Y-L, Liu J, Li J-J, et al. A multi-center survey of achieving recommended lipid goals in Chinese patients with coronary artery disease in real world cardiovascular practice. Int J Cardiol. 2011;153:211-2.
12. Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58:183-9.
13. Huijgen R, Boekholdt SM, Arsenault BJ, et al. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012;59:1778-84.
14. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA. 2005;102:5374-9.
15. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36.
16. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc. 2009; 120:163-73.
17. Lakoski SG, Xu F, Vega GL, et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95(2):800-9.
18. Dubuc G, Tremblay M, Paré G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140-9.
19. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-43.
20. Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010;212:246-51.
21. Konrad RJ, Troutt JS, Cao G. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis. 2011;10:38-47.